Poly(ADP-ribose) polymerase-1 inhibition: Preclinical and clinical development of synthetic lethality

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 854-862

  Leung, Mary ^a   Rosen, David ^b   Fields, Scott ^a   Cesano, Alessandra ^b   Budman, Daniel R ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b Nodality Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; BEVACIZUMAB; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INIPARIB; INO 1001; IRINOTECAN; MITOMYCIN C; MK 4827; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PF 01367338; PZ 01367338; SMALL INTERFERING RNA; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB;

ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIOGRAPHY; BRCA1 ONCOGENE; BRCA2 ONCOGENE; BREAST CANCER; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; EXCISION REPAIR; FALLOPIAN TUBE CANCER; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE DELETION; GLIOBLASTOMA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LETHALITY; LEUKEMIA; LYMPHOMA; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA; NONHODGKIN LYMPHOMA; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY TUMOR; RETROSPECTIVE STUDY; REVIEW; SARCOMA; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR; UTERINE CARCINOSARCOMA; UTERUS CANCER; UTERUS SARCOMA; VOMITING;

ANIMALS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, LETHAL; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79960703030     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00240     Document Type: Review

References (100)

1. Meulmeester E, Jochemsen AG. (2008) p53: a guide to apoptosis. Curr. Cancer Drug Targets.8:87-97.
2. Ames BN, Gold LS. (1991) Endogenous mutagens and the causes of aging and cancer. Mutat. Res. 250:3-16.
3. Hoeijmakers JH. (2001) Genome maintenance mechanisms for preventing cancer. Nature.411:366-74.
4. Bernstein C, Bernstein H, Payne CM, Garewal H. (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: failsafe protection against carcinogenesis. Mutat. Res. 511:145-78.
5. McCabe N, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66:8109-15.
6. Heinen CD, Schmutte C, Fishel R. (2002) DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol. Ther. 1:477-85.
7. Gudmundsdottir K, Ashworth A. (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 25:5864-74.
8. Chen S, et al. (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J. Clin. Oncol. 24:863-71.
9. Lynch HT, Silva E, Snyder C, Lynch JF. (2008) Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 14:3-13.
10. Liede A, Karlan BY, Narod SA. (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 22:735-42.
11. Miyoshi Y, Murase K, Oh K. (2008) Basal-like subtype and BRCA1 dysfunction in breast cancers. Int. J. Clin. Oncol. 13:395-400.
12. Gaymes TJ, et al. (2009) Inhibitors of poly ADPribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica. 94:638-46.
13. Taniguchi T, D'Andrea AD. (2006) Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 107:4223-33.
14. Shammas MA, et al. (2009) Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 113:2290-7.
15. Staff S, Isola J, Jumppanen M, Tanner M. (2010) Aurora-A gene is frequently amplified in basallike breast cancer. Oncol. Rep. 23:307-12.
16. Yamamoto Y, et al. (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer. 16:260-7.
17. Sourisseau T, et al. (2010) Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol. Med. 2:130-42.
18. Sankaran S, Crone DE, Palazzo RE, Parvin JD. (2007) Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosomedependent microtubule nucleation. Cancer Res. 67:11186-94.
19. Moskwa P, et al. (2010) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell. 41:210-20.
20. Ashworth A. (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26:3785-90.
21. Borst P, Rottenberg S, Jonkers J. (2008) How do real tumors become resistant to cisplatin? Cell Cycle. 7:1353-9.
22. Kauffmann A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 27:565-73.
23. Sarasin A, Kauffmann A. (2008) Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat. Res. 659:49-55.
24. Staibano S, et al. (2005) Poly(adenosine diphosphate- ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol. 36:724-31.
25. Anders CK, et al. (2010) Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triplenegative breast cancer. Clin. Cancer Res. 16:4702-10.
26. Annunziata CM, O'Shaughnessy J. (2010) Poly (adp-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res. 16:4517-26.
27. Skipper HE, et al. (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. 54:431-50.
28. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1064-8.
29. Kaelin WG Jr. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer. 5:689-98.
30. Kaelin WG Jr. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1:99.
31. Canaani D. (2009) Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br. J. Cancer. 100:1213-8.
32. Mizuarai S, Irie H, Schmatz DM, Kotani H. (2008) Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr. Mol. Med. 8:774-83.
33. Godon C, et al. (2008) PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 36:4454-64.
34. Schreiber V, Dantzer F, Ame JC, de Murcia G. (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7:517-28.
35. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. (2010) PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer. 10:293-301.
36. Chambon P, Weill JD, Mandel P. (1963) Nicotinamide mononucleotide activation of new DNAdependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11:39-43.
37. Herceg Z, Wang ZQ. (2001) Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res. 477:97-110.
38. Kim MY, Zhang T, Kraus WL. (2005) Poly(ADPribosyl) ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 19:1951-67.
39. Lindahl T, Satoh MS, Poirier GG, Klungland A. (1995) Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci. 20:405-11.
40. Schreiber V, et al. (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277:23028-36.
41. D'Silva I, et al. (1999) Relative affinities of poly(ADP-ribose) polymerase and DNAdependent protein kinase for DNA strand interruptions. Biochim. Biophys. Acta. 1430:119-26.
42. Langelier MF, Servent KM, Rogers EE, Pascal JM. (2008) A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J. Biol. Chem. 283:4105-14.
43. Gradwohl G, et al. (1990) The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc. Natl. Acad. Sci. U. S. A. 87:2990-4.
44. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342:249-68.
45. Oka S, Kato J, Moss J. (2006) Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 281:705-13.
46. Haince JF, et al. (2007) Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J. Biol. Chem. 282:16441-53.
47. Haince JF, et al. (2008) PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem. 283:1197-208.
48. Audebert M, Salles B, Calsou P. (2004) Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 279:55117-26.
49. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. (2004) Effects of novel inhibitors of poly(ADPribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene. 23:7322-9.
50. Wang M, et al. (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 34:6170-82.
51. Caiafa P, Guastafierro T, Zampieri M. (2009) Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 23:672-8.
52. Kraus WL. (2008) Transcriptional control by PARP-1: chromatin modulation, enhancerbinding, coregulation, and insulation. Curr. Opin. Cell Biol. 20:294-302.
53. Shall S, de Murcia G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460:1-15.
54. de Murcia JM, et al. (1997) Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U. S. A. 94:7303-7.
55. Wang ZQ, et al. (1997) PARP is important for genomic stability but dispensable in apoptosis. Genes. Dev. 11:2347-58.
56. Tsutsumi M, et al. (2001) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis. 22:1-3.
57. Hegan DC, et al. (2010) Inhibition of poly(ADPribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci. U. S. A. 107:2201-6.
58. Szanto A, et al. (2009) PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem. Pharmacol. 77:1348-57.
59. Bozulic L, Surucu B, Hynx D, Hemmings BA. (2008) PKBalpha/Akt1 acts downstream of DNAPK in the DNA double-strand break response and promotes survival. Mol. Cell. 30:203-13.
60. Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN. (2005) Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br. J. Pharmacol. 144:772-80.
61. Geraets L, et al. (2007) Flavone as PARP-1 inhibitor: its effect on lipopolysaccharide induced gene-expression. Eur. J. Pharmacol. 573:241-8.
62. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar- Quesada R, et al. (2009) PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic. Biol. Med. 47:13-26.
63. Shevalye H, et al. (2010) Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem. Pharmacol. 79:1007-14.
64. Drel VR, et al. (2010) New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-a. Endocrinology. 151:2547-55.
65. Drel VR, et al. (2009) Poly(adenosine 5'-diphosphateribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Endocrinology. 150:5273-83.
66. Uchida M, et al. (2002) Overexpression of poly(ADP-ribose) polymerase disrupts organization of cytoskeletal F-actin and tissue polarity in Drosophila. J. Biol. Chem. 277:6696-702.
67. Perou CM. (2010) Molecular stratification of triple-negative breast cancers. Oncologist. 15(Suppl. 5):39-48.
68. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9:444-50.
69. Turner N, Tutt A, Ashworth A. (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer.4:814-9.
70. Amir E, Seruga B, Serrano R, Ocana A. (2010) Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev. 36:557-65.
71. Hughes-Davies L, et al. (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 115:523-35.
72. Durkacz BW, Omidiji O, Gray DA, Shall S. (1980) (ADP-ribose)n participates in DNA excision repair. Nature. 283:593-6.
73. Fahrer J, Wagner S, Burkle A, Konigsrainer A. (2009) Rapamycin inhibits poly(ADP-ribosyl)ation in intact cells. Biochem. Biophys. Res. Commun. 386:232-6.
74. Purnell MR, Whish WJ. (1980) Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 185:775-7.
75. Bryant HE, et al. (2005) Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature. 434:913-7.
76. Farmer H, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21.
77. Drew Y, et al. (2010) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 103:334-46.
78. Curtin NJ. (2005) PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. 7:1-20.
79. Evers B, et al. (2008) Selective inhibition of BRCA2- deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14:3916-25.
80. Rottenberg S, et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U. S. A. 105:17079-84.
81. Sandhu SK, Yap TA, de Bono JS. (2010) Poly(ADPribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer. 46:9-20.
82. Edwards SL, et al. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 451:1111-5.
83. Sakai W, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2- mutated cancers. Nature. 451:1116-20.
84. Issaeva N, et al. (2010) 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70:6268-76.
85. Fong PC, et al. (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-34.
86. Tutt A, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235-44.
87. Audeh M, et al. (2009) Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCAdeficient advanced ovarian cancer. J. Clin. Oncol. 27:5500a.
88. Kopetz S, et al. (2008) First in human phase I study of BSI-201, a small molecule inhibitor of poly ADPribose polymerase (PARP) in subjects with advanced solid tumors. J. Clin. Oncol. 26:3579a.
89. Mahany J, et al. (2008) A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced tumors. J. Clin. Oncol. 26:3579a.
90. O. Shaughnessy, et al. (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364:205-14.
91. Ali M, et al. (2009) Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin. Cancer Res. 15:6106-12.
92. Daniel RA, et al. (2009) Inhibition of poly(ADPribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res. 15:1241-9.
93. Plummer R, et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14:7917-23.
94. Plummer R, et al. (2006) First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temazolamide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol. 24:8013a.
95. Donawho CK, et al. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13:2728-37.
96. Kummar S, et al. (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27:2705-11.
97. Roesner JP, et al. (2010) Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock 33:507-12.
98. Morrow DA, et al. (2009) A randomized, placebocontrolled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis. 27:359-64.
99. Bedikian AY, et al. (2009) A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 27:756-63.
100. Mendes-Pereira AM, et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1:315-22.